Investments and investor services
Andalas subsides after finance director resigns
A look at the day's major movers, including Gordon Dadds, Motif Bio, Proton Power, Regal Petroleum, Saga and Xeros Technology
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
743 stories · page 5 of 8
Archive
Proactive news snapshot: ReNeuron Group PLC, Tissue Regenix Group PLC, ANGLE PLC, Motif Bio PLC …
A glance at some of the day's highlights from the Proactive Investors newswire
Hardware & electrical equipment
Frontier IP investee company achieves major milestone in GSK collaboration
Exscientia has delivered a lead molecule using artificial intelligence
Investments and investor services
FTSE 100 closes in positive territory, boosted by better-than-expected US March jobs figures as Brexit uncertainty continues
Mid-cap cousin FTSE 250 was also lower, shedding around 56 points at 19,507
Vectura racks up huge loss following failure of severe asthma inhaler in late-stage study
The drugmaker decided to write down the value of its VR745 asthma treatment to zero following its late-stage trial failure back in November
Frontier IP upgrades full year forecasts as portfolio firm Exscientia inks deal with biotech giant Celgene
The collaboration included an initial upfront payment of US$25mln for Exscientia in addition to “substantial milestones” and tiered royalties on net sales of any product developed
GlaxoSmithKline unit ViiV moves a decisive step closer to producing monthly HIV jab
The update comes in the week that it emerged a third person had possibly been cured of a disease that was during the 1980s considered a death sentence
Builders and building materials
Crest Nicolson appoints Sainsbury executive as new group finance director
Duncan Cooper, the director of group finance at Sainsbury’s, will replace Robert Allen, who left the company in October 2018 following a profit warning
UBS strips GSK of ‘buy’ recommendation on near-term fears for its ViiV HIV division
ViiV has been GSK’s star performer in recent years, but UBS is worried that the launch of a rival HIV drug will see patients switch to other treatments
FTSE 100 closes in the red as US stocks take a hit; Centrica tanks
Risers on the Footsie were outnumbered 3 to 1 by fallers
Archive
Barclays to round off trio of UK banking results on Thursday
Barclays will be a highlight in Thursday's schedule.
Be Heard makes strong start to 2019 after year of transformation
"The group has had a good start to the year," chairman David Morrison said.
Archive
Banking results to flow faster, with Barclays, Lloyds, and HSBC all set to report 2018 numbers
Aside from the banking results, the week ahead will bring updates from other blue-chips firms such as BAE Systems, Anglo American, Pearson, and Reckitt Benckiser
GSK to take £790mln hit from launch of Advair copycat
Dutch pharma giant Mylan won approval from the US Food and Drug Administration last week to launch its version of Advair, which generated sales of almost £2.5bn last year
Investments and investor services
FTSE 100 closes a tad lower ahead of BoE Super Thursday
The UK index of leading shares closed down around four points at 7,173
Archive
Big Pharma is big news for Wednesday as GSK reports results for 2018
The launch of a generic rival to its Advair inhaler has many expecting a downgrade to Glaxo's outlook
Archive
Bank of England's 'Super Thursday' and slew of corporate earnings eyed as Chinese New Year begins
The week ahead includes updates from Thomas Cook, Superdry, Ryanair and Tate & Lyle, among others.
Reckitt Benckiser plunges as US investment bank slams ‘weak’ work culture
“The surprise retirement of CEO Kapoor crystallises long-brewing anxieties. We see no quick fixes and a material risk of a margin re-set under a new CEO.”
GSK chairman steps down after consumer healthcare merger with Pfizer
GSK chairman Sir Philip Hampton said following a deal with Pfizer to merge their consumer businesses, he believes "this is the right moment" to step down
Investments and investor services
FTSE 100 nudges lower at close as China growth worries hit stocks
The UK's blue-chip index finished down nearly seven points at 6,96, while FTSE 250 was also lower
Archive
FTSE 100 closes higher as Wall Street shares mixed; optimism over trade talks fades
The Footsie has been dipping below and above the 6,800 mark throughout the day
Archive
Debenhams set to disappoint again on Thursday
“Debenhams hasn’t updated on trading since 25 October and we know from many of its competitors that November was a terrible month for retailers and December is also likely to have been a struggle”
Archive
Slew of Christmas updates from retailers to dominate after Next's positive seasonal surprise
The Week Ahead will bring trading updates from the likes of M&S and Debenhams on the general retail front and all three of the listed UK supermarket groups – Morrisons, Sainsbury’s, and Tesco
GlaxoSmithKline spikes higher as it inks US$12.7bn consumer healthcare deal with Pfizer
GSK will own 68% of the combined entity, which brings together products such as Panadol and Advil
FTSE 100 closes higher Wednesday; Dow Jones up 1.3%
The UK's premier share index finished over 64 points higher at 6,765
Alliance Pharma bolsters board with addition of two experienced non-execs
Jo Le Couilliard spent much of her career at GSK, while Richard Jones is an ex-investment banker and the current CFO of AIM-listed Mereo Biopharma
GlaxoSmithKline shares drift lower as Morgan Stanley reinitiates coverage with ‘underweight’ stance
The US investment bank set a price target of 1,460p on the FTSE 100-listed firm, with Glaxo's shares trading at 1,476.20p late morning, down 0.4% on Thursday’s closing price
Archive
Lloyds, Vodafone, BP, GSK and Sirius Minerals the top traded companies of 2018
The Share Centre's Helal Miah said Lloyds' dividends have been restored to historic norms as profits have recovered after its restructuring
Sterling slump: Who’s benefitting?
On Monday, fresh Brexit volatility pushed the pound to a yearly low against the dollar but despite the turmoil, some firms are profiting handsomely
Barclays downgrades GSK; warns of “significant EPS dilution” from Tesaro acquisition
Barclays reckons the GSK valuation remains appealing, but is waiting until 2019 before piling back in, as it thinks the shares might drift a little lower yet
Delays to Mylan’s Wixela inhaler to hit Consort Medical’s annual profits by £3mln
The US FDA has twice rejected Wixela, and despite Mylan’s claims that approval is around the corner, the green light is yet to be shown
GSK to buy US cancer drug firm Tesaro after making a Horlicks with Unilever
GSK said the acquisition will support "our aim to deliver long-term sustainable growth and is consistent with our capital allocation priorities"
GlaxoSmithKline sells Indian Horlicks business to Unilever
The US$3.8bn deal covers GSK’s health food and drinks portfolio in India, Bangladesh, and 20 other predominantly Asian markets
FTSE 100 clings on to triple-digit gain
The Footsie looked destined to finish well off the top but still sporting a handsome gain following a weekend of deals at the G20 and Opec meetings
GSK confirms it is considering merger of consumer healthcare unit
The possible merger is part of a strategic review of GSK’s Indian Horlicks business and other consumer healthcare nutrition products
Unilever in exclusive talks to acquire GlaxoSmithKline's Indian Horlicks nutrition business - report
However, Indian newspaper Times of India reported that Swiss consumer products rival Nestlé SA is close to buying Horlicks and other Glaxo consumer healthcare assets
Investments and investor services
FTSE 100 closes marginally higher as PM May defends draft Brexit deal
The UK's premier share index closed up around four points at 7,038, while the FTSE 250 shed almost 248 points at 18,662.
Archive
Royal Mail profit warning and management changes to overshadow first half results
The day ahead includes first half results from Royal Mail and a third quarter trading update from Bovis Homes
Archive
Proactive news snapshot: Haydale Graphene Industries, Tissue Regenix, to Hurricane Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
BTG shares gain on solid interims while Interserve slumps for second day in a row
A look at the day's gainers and painers, including Vodafone, FirstGroup and Haydale Graphene
Investments and investor services
FTSE 100 flatlines at close as sterling gains on Brexit optimism
The UK blue-chip benchmark closed up 0.68 at 7,053, while the FTSE 250 added over 174 points at 18,985
Growing opportunities in respiratory space could accelerate Circassia’s path to profitability, says analyst
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
Archive
Housebuilders to take centre stage again after Persimmon boss drama
The week ahead includes trading updates from Bovis Homes and Taylor Wimpey, full year results from McCarthy & Stone, interims from Royal Mail, Vodafone and Premier Foods along with a batch of UK data
Hikma and Vectura to develop generic version of GSK’s blockbuster Ellipta inhaler
It is not the first time the pair have targeted Glaxo, they have previously developed a cut-price version of Advair
GSK ups full-year earnings forecasts on strong sales of Shringrix vaccine
The FTSE 100 drugmaker now expects full-year adjusted earnings per share to climb by 8-10% in 2018, while it is also guiding for overall full-year performance at the upper end of previous expectations
Investments and investor services
FTSE 100 closes firmly ahead as it puts dismal October to rest
The FTSE 100 closed up around 92 points at 7,182. FTSE 250 also gained..
GlaxoSmithKline releases upbeat injectable HIV treatment results
Trials for ViiV Healthcare's once-a-month injection show it is as effective as the current standard of care for HIV patients
Archive
Glaxo getting the tingles from its shingles jab
Trading updates from Glaxo, Standard Chartered and Next are likely to be the highlights
Archive
UK Budget, BoE, US jobs data to sandwich flood of corporate updates from likes of BP and Shell
Aside from the oil majors, the slew of blue-chip updates due in the coming week will include global banks HSBC and Standard Chartered, and drugs firms GlaxoSmithKlne and Shire
Investments and investor services
FTSE 100 closes down nearly 2% as the big sell-off continues
The UK blue-chip benchmark finished down nearly 139 points lower at 7,006 - not far from the 7,000 mark
Archive
Hays to receive boost from German operations
Solid results from sector peer PageGroup should give Hays shareholders cause to feel optimistic
Archive
Retailers and recruiters in week ahead spotlight with results from N Brown, WH Smith, PageGroup and Hays
The week ahead sees updates from N Brown, WH Smith, Hays, PageGroup, Greggs, RPC Group and Marston's
FTSE 100 closes higher as US stocks surge
The UK's premier index closed up around 36 points at 7,367.
Investments and investor services
Diageo expected to be the toast of Thursday’s market news
Diageo and Lamprell are expected to be among the names under focus in Thursday's schedule.
New contract wins with UK blue-chips help first-half revenues soar at Be Heard
New business from the likes of Vodafone and GSK and a strong contribution from The Corner, which it acquired in December, meant revenues jumped 70% in the first half
Archive
UK inflation and retail sales data eyed, plus trading updates from Kingfisher and Ocado
Aside from the UK data and the retail updates, the Week Ahead will also bring news from the likes of Diageo, Dairy Crest, Smiths Group, Lamprell, and SIG
Immutep valuation increased 16% to $510 million by Edison Investment Research
The research note puts the value per share at 14 cents each, or 12 cents after dilutions.
GSK downgraded by Liberum to 'hold' as broker sees better value elsewhere
Liberum downgraded GSK to a ‘hold’ rating from ‘buy’ but raised its target price to 1,700p from 1,630p
GlaxoSmithKline offshoot makes HIV breakthrough
The once-a-month jab developed by ViiV Healthcare could replace a daily cocktail of drugs currently prescribed
Investments and investor services
FTSE 100 closes deep in red as Turkey/US worries escalate
Footsie closed down 1.49%, or around 114 points, at 7,497 on the day
Archive
Cineworld investors hope World Cup and hot weather failed to keep customers away in first-half
The day ahead sees Cineworld and Legal & General report their first-half results
GlaxoSmithKline appoints HSBC bean counter on pay, perks package worth up to £3.4mln
Iain Mackay joins the international drugs giant next January
Archive
HSBC will ring down the curtain on the bank's interim reporting season, but other financials also in focus
Aside from HSBC's numbers, Prudential, L&G, Standard Life Aberdeen, and Hargreaves Lansdown are all on the results docket in the coming week
Equiniti shares jump as it expects full-year earnings to reach top end of market forecasts
Equiniti said revenues were boosted by contract renewals and new client wins
FTSE 100 closes higher, boosted by earnings and weaker pound
In London, FTSE 100 added over 38 points to finish at 7,701 - that was up on the week too, marginally - by 0.29%.
FDA committee doesn’t think GSK’s asthma drug can be used to treat COPD as well
Nucala has already been approved to treat asthma patients, but an FDA advisory committee isn't convinced there is enough data to back up GSk's belief that it can help COPD patients as well
GSK unveils new £1.7bn cost-cutting programme as it switches tack on R&D
GSK reckons the changes can save it £400mln a year, while it wants to shift its R&D focus towards immunotherapies and genetics
FTSE 100 closes down as market awaits Trump/Juncker meeting
The UK blue-chip index closed around 50 points lower at 7,658, while FTSE 250 was also down - over 99 points at 20,753
GSK publishes more positive data from HIV trials ahead of Wednesday’s Q2 update
Juluca has been shown to be effective over the course of two years, while GSK’s other two-drug combo supressed the virus in untreated HIV sufferers
Investments and investor services
ITV, GlaxoSmithKline and Indivior to be among the highlights for Wednesday
Among Wednesday's names are ITV, GlaxoSmithKline, Indivior, and Tullow Oil
Archive
FTSE 100 starts week by ending lower as geopolitical woes hit sentiment...again
In London, FTSE 100 shed 23 points to 7,655, while FTSE 250 shed over 155 points at 20,770
GlaxoSmithKline considering business break-up following investor pressure - FT report
The newspaper said GSK’s chairman Philip Hampton has been in discussions with the FTSE 100-listed group’s biggest shareholders about the creation of a standalone pharma and vaccines company in the medium term
Archive
Apres moi le deluge: Flood of blue chip results to dominate in coming week, including BT Group
Over the five sessions in the Week Ahead, around 20% of the FTSE 100 index will report results or issue a trading update, with about half that number due on Thursday alone
Investments and investor services
FTSE 100: Forget Brexit, here’s what we’ll learn from a bumper earnings week
We have a deluge of earnings statements from some of Britain's biggest businesses. Below we discuss the themes likely to emerge from the mid-term reporting season
Archive
ASOS set for a warm weather boost
Thursday will see retailers ASOS and Dunelm to the fore. The former is expected to issue an upbeat statement while the latter will be looking to prove it is not curtains for its growth story.
Archive
High street vs online: Updates from retailers Mark & Spencer and ASOS will provide fuel
Aside from M&S and ASOS, the week ahead will also bring trading updates from the likes of Ocado, Burberry, Barratt Development, Experian, and JD Wetherspoon
GlaxoSmithKline gets double target price lift from Barclays and Deutsche Bank on growth expectations
Analysts at both investment banks expected EPS growth for the FTSE 100 pharma group, while also expecting more clarity from GSK's new head of research and development
NeuroMetrix shares pop after receiving milestone payment under tie-up with GlaxoSmithKline
NeuroMetrix has ceded ownership of its Quell technology for markets outside the US to Glaxo's consumer health care division
Bidding war brewing for GSK’s Indian Horlicks division, with Coca-Cola, Nestle and Kraft all reportedly interested
Horlicks might not be big business in the UK anymore, but it is India, where hundreds of thousands of kids drink it every day for breakfast
GlaxoSmithKline reports positive results from phase III trial of its two-drug HIV treatment
The GEMINI trials showed that HIV could be treated with a two-drug regimen, as opposed to the cocktail of three or more drugs which sufferers currently have to take
Glaxo makes new drug application in Japan for COPD treatment, Trelegy Ellipta
"We look forward to a decision from the MHLW, which, if positive, would provide a new therapeutic option for appropriate patients with COPD in Japan," said Dr Ted Witek, the senior vice president and chief scientific officer at Innoviva
Investments and investor services
FTSE 100 closes higher, given a leg-up by weaker pound
The blue-chip index closed around 38 points higher at 7,700
Investments and investor services
Will BT Group be able to avoid cutting its dividend?
Thursday is set to be a busy one for corporate results with the likes of BT Group, Barratt Developments, Next and Supergroup among the day's highlights.
GlaxoSmithKline CFO Simon Dingemans to retire next May
Simon Dingemans has been with GSK for seven years, but he will hang up his boots in 12 months’ time
Archive
Rate hike unlikely from May Bank of England policy meeting after recent dull UK data
Aside from the latest Bank of England interest rate decision, the week ahead includes updates from Wm Morrison Supermarkets, Next, BT Group, ITV, and William Hill ...
GSK rules out Shire bid as it reports drop in quarterly earnings
The drugmaker reported a 2% decline in first quarter adjusted earnings as a stronger pound and pricing pressure provided a drag
Stellar Diamonds shares leap as court approves its acquisition by NWF
A look at some of the biggest risers and fallers in London on Wednesday
FTSE 100 pares losses as US bond yields rise above 3%
Resource stocks suffer as US dollar makes headway on forex markets
Archive
Big results day for banks and drugs as Lloyds and GlaxoSmithKline step up to the plate
Day ahead includes first-quarter updates from blue chip firms Lloyds Banking Group, GlaxoSmithKline, Whitbread, and Persimmon ...
Investments and investor services
FTSE 100 closes higher, buoyed by hopes for City post-Brexit
FTSE 100 closed around 30 points higher at 7,398 on Minday
Archive
Lloyds, Barclays, RBS, GSK and Shire kick off earnings season for banks and pharmas
The week ahead in includes updates from Lloyds, Barclays, RBS, Shire, GSK, Whitbread, Persimmon and Shell
AstraZeneca and GlaxoSmithKline share price targets tweaked and on Jefferies' 'buy' ahead of Q1 results season for the druggies
The broker is still enamoured of the UK big hitters but doesn't expect it to be plain sailing for either
Strong growth in portfolio value matched by share price rise for incubator Frontier IP Group
The AIM-listed intellectual property group’s investments were worth £8mln as at the end of December 2017, helped by the additions of The Vaccine Group and water pollution tester Molendotech
GSK buys out consumer healthcare venture partner Novartis for US$13bn
The news comes just days after GSK bowed out of the race to take over the consumer healthcare unit of Pfizer
FTSE 100 stages rebound as trade war fears ease
In the currency markets, the pound shed 0.17% against the Euro, and lost 0.46% against the US dollar
GlaxoSmithKline follows Reckitt Benckiser in bowing out of US$20bn auction for Pfizer consumer division
Bidders seem to be dropping like flies and it's unclear just who is left in the auction
FTSE 100 closes down on trade war concerns as market awaits Brexit transition deal approval
Will EU leaders approve the Brexit transition deal reached between Michel Barnier and David Davis?
Reckitt clears way for GSK to buy Pfizer's consumer healthcare unit after ending talks
“An acquisition for the whole Pfizer consumer health business did not fit our acquisition criteria," said Reckitt boss Rakesh Kapoor
Investments and investor services
FTSE 100 plunges 1.23% to below 7,000 after BoE rate decision
In the currency markets, the pound is up 0.13% against the Euro, but down 0.20% against the US dollar.
Hikma Pharmaceuticals and Vectura hit by US regulatory setback
Hikma hit a roadblock with the US Food & Drug Administration as it lodged an abbreviated new drug application for asthma treatment Advair Diskus, first developed by GlaxoSmithKline